NBIX -Long -TP>25%NASDAQ:NBIX
- LONG - RISK 1/5 - TP > 25%
We already have a buy position.
Good luck to everyone...
==============================
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.86 USD
249.70 M USD
1.89 B USD
99.05 M
About Neurocrine Biosciences, Inc.
Sector
CEO
Kyle W. Gano
Headquarters
San Diego
Website
Founded
1992
FIGI
BBG000GJS7C1
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
NBIX -Long -TP>25%NASDAQ:NBIX
-Long
-TP>25-30% and more
-waiting for a point to enter a long position
Solid Growth but Misses Q2 Earnings TargetsNeurocrine Biosciences Inc. (NASDAQ: NBIX) is continuing to advance its position in the biotech sector, despite facing a slight setback in its Q2 2024 earnings report. The company posted revenue of $590.2 million, which was higher than analyst estimates of $545.9 million, representing a 30.4% year-o
Textbook bullish flagIt looks like a beautiful flag (or pennant) to me, with high volume at the pole and the volume drying up during the consolidation.
I am expecting continuation.
(Potential Trade) NBIX(13 May 2024)
Disclaimer:
All information posted are the author's own trades/potential trades.
The author is not a certified Financial Advisor and do not have the certifications to provide financial advice.
These information are strictly for educational purposes only and do not constitute any finan
NBIX Biotechnology / Pharmaceutical Pre-earnings LONGNeurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th.
Investor and trader interest seems to be moderately increasing in the past week. The combined
MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket
before 7:45 AM
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges
Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidat
Neurocrine Biosciences (NBIX: NASDAQ)Neurocrine Biosciences (NBIX), a biotech company specializing in treatments for neurological, endocrine, and psychiatric disorders, is poised for opportunities in congenital adrenal hyperplasia (CAH). Analysts project NBIX to potentially achieve worldwide revenue of $660 million by fiscal year 2030,
NBIX view(personal)For this stock i have done some deep analysis including looking at the financial reports and estimated points provided by big bank analyst. i have come to the conclusion that after this close below the strong daily support. this pair is likely going to go to the 95 dollar zone within 2 weeks and fr
$NBIX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for $NBIX after a negative under reaction following its earnings release placing the stock in drift D .
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NBIX is featured.
Frequently Asked Questions
The current price of NBIX is 125.74 USD — it has increased by 1.42% in the past 24 hours. Watch Neurocrine Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neurocrine Biosciences, Inc. stocks are traded under the ticker NBIX.
NBIX stock has risen by 4.33% compared to the previous week, the month change is a 12.50% rise, over the last year Neurocrine Biosciences, Inc. has showed a 8.57% increase.
We've gathered analysts' opinions on Neurocrine Biosciences, Inc. future price: according to them, NBIX price has a max estimate of 192.00 USD and a min estimate of 121.00 USD. Watch NBIX chart and read a more detailed Neurocrine Biosciences, Inc. stock forecast: see what analysts think of Neurocrine Biosciences, Inc. and suggest that you do with its stocks.
NBIX reached its all-time high on Aug 1, 2024 with the price of 157.98 USD, and its all-time low was 1.94 USD and was reached on Nov 30, 2009. View more price dynamics on NBIX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NBIX stock is 2.04% volatile and has beta coefficient of 0.43. Track Neurocrine Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neurocrine Biosciences, Inc. there?
Today Neurocrine Biosciences, Inc. has the market capitalization of 12.73 B, it has increased by 7.63% over the last week.
Yes, you can track Neurocrine Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Neurocrine Biosciences, Inc. is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
NBIX earnings for the last quarter are 1.24 USD per share, whereas the estimation was 1.52 USD resulting in a −18.24% surprise. The estimated earnings for the next quarter are 1.59 USD per share. See more details about Neurocrine Biosciences, Inc. earnings.
Neurocrine Biosciences, Inc. revenue for the last quarter amounts to 622.10 M USD, despite the estimated figure of 600.64 M USD. In the next quarter, revenue is expected to reach 629.55 M USD.
NBIX net income for the last quarter is 129.80 M USD, while the quarter before that showed 65.00 M USD of net income which accounts for 99.69% change. Track more Neurocrine Biosciences, Inc. financial stats to get the full picture.
No, NBIX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 1.40 K employees. See our rating of the largest employees — is Neurocrine Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neurocrine Biosciences, Inc. EBITDA is 614.00 M USD, and current EBITDA margin is 22.05%. See more stats in Neurocrine Biosciences, Inc. financial statements.
Like other stocks, NBIX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neurocrine Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neurocrine Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neurocrine Biosciences, Inc. stock shows the buy signal. See more of Neurocrine Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.